Page URL:

Biotech company Editas to begin human gene editing in 2017

16 November 2015
Appeared in BioNews 828

A US biotechnology start-up co-founded by two pioneers of CRISPR technology intends to begin gene editing in humans as part of an experimental treatment to target a rare genetic eye disorder.

Katrine Bosley, CEO of Editas Medicine, announced that research involving the technique, CRISPR/Cas9, will begin to tackle leber congenital amaurosis (LCA), with a clinical trial expected in 2017.

The treatment would involve injecting the retina, the light-sensitive layer of cells at the back of the eye, with modified viruses carrying CRISPR/Cas9. This would be used to delete a portion of DNA in the CEP290 gene, believed to be implicated in the disorder.

People affected with LCA have difficulty seeing anything other than large, bright shapes from infancy. The condition was selected for the first trial as it is easy to target with CRISPR/Cas9, Bosley explained. Additionally, as it affects vision, the success or otherwise will be more obvious afterwards. It is estimated that around 600 people in the USA are affected by the type of LCA that Editas plans to treat.

The use of federal funds for gene editing in human embryos is currently banned in the USA (see BioNews 800) and Editas will also require approval from regulators before embarking upon the trial.

The technology has attracted controversy over safety and ethical concerns about editing the germline in a way that would affect future generations. CRISPR/Cas 9 has so far only been tested in animals and non-viable human embryos.

'It feels fast, but we are going at the pace science allows', Bosley told the EmTech conference in Cambridge, Massachusetts.

Editas was co-founded by Professors Jennifer Doudna and Feng Zhang, who are currently embroiled in a patent dispute over the CRISPR/Cas9 technique (see BioNews 802). In August, it raised US $120 (£80) million from investors to fund research like the kind being done with LCA.

The MIT Technology Review says that Editas is one of a number of start-ups that plan to use CRISPR techniques to target genetic conditions in people, partly because it is so cheap to use but also for its precise application. 

The Progress Educational Trust's public conference 'From Three-Person IVF to Genome Editing: The Science and Ethics of Engineering the Embryo' is taking place in central London on Wednesday 9 December 2015. Find out more here.

21 November 2016 - by Paul Waldron 
Scientists in the US have used a genome-editing technique to partially restore vision in blind rats...
8 February 2016 - by Cait McDonagh 
A biotechnology company co-founded by two leading scientists involved in developing the genome-editing technology, CRISPR/Cas9, has gone public, raising over $94 million in its initial share offering...
11 January 2016 - by Paul Waldron 
Researchers have improved the genome-editing technique CRISPR/Cas9, reducing errors to nearly undetectable levels, according to a new study...
7 December 2015 - by Dr Jane Currie 
An international summit has agreed conditions under which human genome editing, using techniques like CRISPR, should proceed...
30 November 2015 - by Dr Silvia Camporesi and Dr Lara Marks 
It is important to engage the public in the debate about genome editing as early as possible, and in a way that is as open as possible, to make sure that all possible voices are included...
26 October 2015 - by Isobel Steer 
Scientists in China have used the gene-editing technique CRISPR/Cas9 to create dogs with increased muscle mass...
26 October 2015 - by Paul Waldron 
Scientists have used 'genome surgery' to change the way DNA is packed inside human cells...
19 October 2015 - by Jessica Richardson 
Researchers say that the gene-editing technique CRISPR/Cas9 could be used to increase the safety of organ transplantation from pig to human...
13 February 2012 - by Dr Maria Botcharova 
Three women have reported a significant improvement in sight following gene therapy in both their eyes. Initially, they received the therapy in just one eye, but this latest study demonstrates the treatment was also successful in the other...
27 September 2010 - by Dr Rachael Panizzo 
Researchers have successfully transplanted retinal cone cells into blind mice, making progress towards a stem cell treatment for a form of blindness that causes degeneration of the eye's retina...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.